Switch theme
Sign up to access all valuation multiples
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
1996
2.2K+
LTM Revenue $981M
LTM EBITDA $230M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genomma Lab has a last 12-month revenue (LTM) of $981M and a last 12-month EBITDA of $230M.
In the most recent fiscal year, Genomma Lab achieved revenue of $960M and an EBITDA of $213M.
Genomma Lab expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genomma Lab valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $981M | XXX | $960M | XXX | XXX | XXX |
| Gross Profit | $981M | XXX | $615M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $230M | XXX | $213M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $212M | XXX | $201M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $118M | XXX | $77.0M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $214M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genomma Lab's stock price is MXN 22 (or $1).
Genomma Lab has current market cap of MXN 21.8B (or $1.1B), and EV of MXN 26.6B (or $1.4B).
See Genomma Lab trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.1B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genomma Lab has market cap of $1.1B and EV of $1.4B.
Genomma Lab's trades at 1.4x EV/Revenue multiple, and 6.4x EV/EBITDA.
Equity research analysts estimate Genomma Lab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genomma Lab has a P/E ratio of 9.6x.
See valuation multiples for Genomma Lab and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 6.0x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBIT | 6.5x | XXX | 6.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.6x | XXX | 14.6x | XXX | XXX | XXX |
| EV/FCF | 11.7x | XXX | 11.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenomma Lab's last 12 month revenue growth is 5%
Genomma Lab's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Genomma Lab's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genomma Lab's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genomma Lab and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 30% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomma Lab acquired XXX companies to date.
Last acquisition by Genomma Lab was XXXXXXXX, XXXXX XXXXX XXXXXX . Genomma Lab acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genomma Lab founded? | Genomma Lab was founded in 1996. |
| Where is Genomma Lab headquartered? | Genomma Lab is headquartered in Mexico. |
| How many employees does Genomma Lab have? | As of today, Genomma Lab has 2.2K+ employees. |
| Is Genomma Lab publicy listed? | Yes, Genomma Lab is a public company listed on MEX. |
| What is the stock symbol of Genomma Lab? | Genomma Lab trades under LABB ticker. |
| When did Genomma Lab go public? | Genomma Lab went public in 2008. |
| Who are competitors of Genomma Lab? | Similar companies to Genomma Lab include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Genomma Lab? | Genomma Lab's current market cap is $1.1B |
| What is the current revenue of Genomma Lab? | Genomma Lab's last 12 months revenue is $981M. |
| What is the current revenue growth of Genomma Lab? | Genomma Lab revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Genomma Lab? | Current revenue multiple of Genomma Lab is 1.4x. |
| Is Genomma Lab profitable? | Yes, Genomma Lab is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genomma Lab? | Genomma Lab's last 12 months EBITDA is $230M. |
| What is Genomma Lab's EBITDA margin? | Genomma Lab's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Genomma Lab? | Current EBITDA multiple of Genomma Lab is 6.0x. |
| What is the current FCF of Genomma Lab? | Genomma Lab's last 12 months FCF is $118M. |
| What is Genomma Lab's FCF margin? | Genomma Lab's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Genomma Lab? | Current FCF multiple of Genomma Lab is 11.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
